Gyros and SCRUM sign distribution agreement for the Japanese market


Gyros AB, the leading provider of automated micro-immunoassays for the development of biotherapeutics, is pleased to announce the signing of an exclusive distribution agreement with SCRUM, a major supplier to the Japanese life-science market. Under the terms of the agreement, SCRUM will market, sell and fully support the Gyros product range, within the Japanese biopharmaceutical, contract research and contract manufacturing industries.

The Gyrolab system from Gyros is increasingly being employed by leading biopharmaceutical companies, and their contracted service organizations, during drug development and clinical trials. The company’s success in Europe and the USA has encouraged its expansion into Asia-Pacific, where Japan is regarded as a major market.

“We are very happy to have such an experienced and well-established organization as SCRUM representing our products in the Japanese market”, commented Erik Walldén, CEO and President of Gyros. “We believe that Japan represents a key market for us and that this agreement with SCRUM will lead to a significant expansion of our presence in the Asia-Pacific region.”

Mr. Takemitsu Furuta, Strategic Marketing Director of SCRUM commented, “The value of this revolutionary platform from Gyros has already been well recognized by many pharmaceutical companies and contract research organizations in Europe and the US. We anticipate a similar response in Japan, and are keen for the opportunity to introduce a technology that we strongly believe will facilitate studies and increase our customers’ efficiency. We are looking forward to the first official introduction at our exhibition stand during the upcoming 83rd Annual Meeting of the Japanese Pharmacological Society, in March, 2010.”

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.